Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02UYB
|
|||
| Former ID |
DIB003380
|
|||
| Drug Name |
Patisiran
|
|||
| Synonyms |
Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328
Click to Show/Hide
|
|||
| Drug Type |
siRNA drug
|
|||
| Indication | Amyloidosis [ICD-11: 5D00; ICD-9: 277.3] | Approved | [1] | |
| Hereditary amyloidosis [ICD-11: 5D00.2; ICD-10: E85.2] | Approved | [2] | ||
| Amyloid cardiomyopathy [ICD-11: 5D00.20; ICD-10: E85.1] | Phase 3 | [3] | ||
| Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20; ICD-10: E85.1] | Phase 3 | [4] | ||
| Company |
Alnylam Pharmaceuticals
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transthyretin messenger RNA (TTR mRNA) | Target Info | . | [5] |
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | |||
| Reactome | Retinoid cycle disease events | |||
| The canonical retinoid cycle in rods (twilight vision) | ||||
| Non-integrin membrane-ECM interactions | ||||
| Retinoid metabolism and transport | ||||
| Amyloid formation | ||||
| WikiPathways | Visual phototransduction | |||
| Extracellular matrix organization | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 210922. | |||
| REF 2 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT01960348) APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis. U.S. National Institutes of Health. | |||
| REF 5 | Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.